Loading
The freshest signals in cancer: new papers, trial results, approvals and law, updated with every build.
Ranked newest first, with approvals, withdrawals and phase 3 results counting as two weeks fresher than their date, other results, law and papers in the leading journals one week fresher, and preprints one week older; every kind keeps its most recent items so no filter is empty while its source has data. Within a day the weightier items come first. Pick types to combine them; For you narrows to the cancer chosen in For me (a choice that stays in this browser); the first filter reads the full 500-item feed.
200 items on this page.
705 changelog entries, 1 regulatory event, 1 upcoming date, 8 corrections.
567 changelog entries, 1 regulatory event, 1 upcoming date, 4 corrections.
Published in Endocr Relat Cancer on 23 September 2026; matched the OnCo record for CYP11B1.
Published in Adv Sci (Weinh) on 23 September 2026; matched the OnCo record for HMGA2.
Published in Gut Microbes on 23 September 2026; matched the OnCo record for SIRT1.
Published in Mol Oncol on 23 September 2026; matched the OnCo record for ARID1A.
Published in Am J Physiol Cell Physiol on 23 September 2026; matched the OnCo record for HEY1.
Published in J Cell Sci on 23 September 2026; matched the OnCo record for FGD1.
Published in Comput Methods Biomech Biomed Engin on 23 September 2026; matched the OnCo record for SLC6A2.
Published in J Int Med Res on 23 September 2026; matched the OnCo record for RNASET2.
Published in Funct Integr Genomics on 23 September 2026; matched the OnCo record for HRAS.
491 changelog entries, 1 regulatory event, 1 upcoming date, 2 corrections.
Published in Nat Med on 22 September 2026; found by the roadmap watch for PATHFINDER 2.
Published in Cell on 22 September 2026; matched the OnCo record for IRF1.
Published in Cancer Discov on 22 September 2026; matched the OnCo record for BMP2.
Published in J Biol Chem on 22 September 2026; matched the OnCo record for ETV5.
Published in Cell Rep on 22 September 2026; matched the OnCo record for USP28.
Published in J Biol Chem on 22 September 2026; matched the OnCo record for CDA.
Published in JMIR Bioinform Biotechnol on 22 September 2026; matched the OnCo record for ERCC2.
Published in J Neurooncol on 22 September 2026; matched the OnCo record for TP53BP1.
Published in Emerg Microbes Infect on 22 September 2026; matched the OnCo record for ATM.
Published in Transl Oncol on 22 September 2026; matched the OnCo record for ARID2.
Published in Kidney Int on 22 September 2026; matched the OnCo record for AREG.
Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for TUBB3.
Published in Mol Biomed on 22 September 2026; matched the OnCo record for HBB.
Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for ERCC1.
Published in Transl Oncol on 22 September 2026; matched the OnCo record for MAPK8.
Published in Oncoimmunology on 22 September 2026; matched the OnCo record for IL2RB.
Published in Mol Cell Endocrinol on 22 September 2026; matched the OnCo record for ALDH2.
Published in Genomics on 22 September 2026; matched the OnCo record for DLST.
Published in Breast Cancer Res Treat on 22 September 2026; matched the OnCo record for Invasive lobular carcinoma of the breast.
Published in Head Neck Pathol on 22 September 2026; matched the OnCo record for PLAG1.
Published in Nucleosides Nucleotides Nucleic Acids on 22 September 2026; matched the OnCo record for HOXA9.
Published in JHEP Rep on 22 September 2026; matched the OnCo record for AXIN1.
Published in Oncoimmunology on 22 September 2026; matched the OnCo record for CD80.
Published in JCI Insight on 22 September 2026; matched the OnCo record for SRMS.
Published in Biochim Biophys Acta Mol Basis Dis on 22 September 2026; matched the OnCo record for ITPR1.
451 changelog entries, 1 regulatory event, 2 upcoming dates, 2 corrections.
Published in Dev Neurosci on 22 September 2026; matched the OnCo record for CX3CL1.
Published in Cancer Gene Ther on 22 September 2026; matched the OnCo record for NFATC2.
Published in Ann Rheum Dis on 22 September 2026; matched the OnCo record for BCL6.
Published in Elife on 22 September 2026; matched the OnCo record for SFPQ.
Published in Mol Med on 22 September 2026; matched the OnCo record for HDAC5.
Published in JHEP Rep on 22 September 2026; matched the OnCo record for PSEN2.
Published in Br J Cancer on 22 September 2026; matched the OnCo record for TNC.
Published in JCI Insight on 22 September 2026; matched the OnCo record for MEF2D.
Published in J Vis Exp on 22 September 2026; matched the OnCo record for BMP7.
Published in Cell Rep on 22 September 2026; matched the OnCo record for CBL.
Published in Org Biomol Chem on 22 September 2026; matched the OnCo record for CCND3.
Published in Proc Natl Acad Sci U S A on 22 September 2026; matched the OnCo record for CREBBP.
Published in Biochem J on 22 September 2026; matched the OnCo record for MERTK.
Published in J Pediatr Endocrinol Metab on 22 September 2026; matched the OnCo record for Paediatric low-grade glioma.
Published in J Pathol on 22 September 2026; matched the OnCo record for CX3CL1.
Published in G3 (Bethesda) on 22 September 2026; matched the OnCo record for ETV4.
Published in Rev Esp Patol on 22 September 2026; matched the OnCo record for DDIT3.
Published in Wien Klin Wochenschr on 22 September 2026; matched the OnCo record for FGF23.
Published in Transfusion on 22 September 2026; matched the OnCo record for ABO.
Published in Int J Surg Pathol on 22 September 2026; matched the OnCo record for NCOA2.
Published in EMBO Rep on 22 September 2026; matched the OnCo record for CEBPA.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Single-cell & spatial profiling.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CAR-T cell therapy and Aldesleukin.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched Fulvestrant, HER3 and AKT.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched RNA sequencing & expression profiling, BRCA1 / BRCA2 and Long-read sequencing.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Atlas.
Posted on Research Square on 22 September 2026; not peer reviewed; matched MET.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched ATR.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched GD2, Bispecific antibodies and Antibody-drug conjugate.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and BRCA1 / BRCA2.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched CSF1R.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Liquid biopsy.
Posted on bioRxiv on 22 September 2026; not peer reviewed; matched PARP inhibitors, PARP and ATR.
Posted on Research Square on 22 September 2026; not peer reviewed; matched AI trial matching & clinical decision support and BioEmu.
Posted on Research Square on 22 September 2026; not peer reviewed; matched Chemoprevention & risk-reducing surgery.
Published in Blood on 21 September 2026; matched the OnCo record for LMNA.
Published in Blood Cancer Discov on 21 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.
Published in eNeuro on 21 September 2026; matched the OnCo record for SOS1.
Published in Kidney Int on 21 September 2026; matched the OnCo record for SOX9.
Published in Muscle Nerve on 21 September 2026; matched the OnCo record for Small intestine cancer.
Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for BIM.
Published in 3 Biotech on 21 September 2026; matched the OnCo record for YAP1.
Published in Transl Oncol on 21 September 2026; matched the OnCo record for FGA.
Published in J Immunother on 21 September 2026; matched the OnCo record for Human normal immunoglobulin.
Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published in Biochem Pharmacol on 21 September 2026; matched the OnCo record for THRB.
Published in Pediatr Blood Cancer on 21 September 2026; matched the OnCo record for Acute myeloid leukaemia in children.
Published in Elife on 21 September 2026; matched the OnCo record for LMO2.
Published in Cytotechnology on 21 September 2026; matched the OnCo record for CASP8.
Published in Eur J Gen Pract on 21 September 2026; matched the OnCo record for LPA.
Published on 21 September 2026 after first appearing as a preprint; matched Med-Gemini and MedLM and State.
Published in J Oral Pathol Med on 21 September 2026; matched the OnCo record for BMP2.
Published in Vasc Biol on 21 September 2026; matched the OnCo record for TEC.
Published in Exploration (Beijing) on 21 September 2026; matched the OnCo record for Mebendazole.
Published in Epigenomics on 21 September 2026; matched the OnCo record for Papillary carcinoma of the gallbladder.
Published in Plant Physiol Biochem on 21 September 2026; matched the OnCo record for TPT1.
Published in Transl Oncol on 21 September 2026; matched the OnCo record for GMPS.
Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for RBX1.
Published in Cancer Immunol Res on 21 September 2026; matched the OnCo record for TCR-T cell therapy.
Published in Free Radic Biol Med on 21 September 2026; matched the OnCo record for FOXO3.
Published in Signal Transduct Target Ther on 21 September 2026; matched the OnCo record for Aumolertinib.
Published in Genet Test Mol Biomarkers on 21 September 2026; matched the OnCo record for CYP17A1.
Published in Adv Mater on 21 September 2026; matched the OnCo record for CCND2.
Published in J Thorac Oncol on 21 September 2026; matched the OnCo record for LTB.
Published on 21 September 2026 after first appearing as a preprint; matched Single-cell & spatial profiling.
Published in Br J Cancer on 21 September 2026; matched the OnCo record for CBL.
Published in Transl Oncol on 21 September 2026; matched the OnCo record for TCL1A.
310 changelog entries, 1 upcoming date, 7 publications, 2 corrections.
Published in J Immunother Cancer on 21 September 2026; matched the OnCo record for CCND2.
Published in Eur Radiol Exp on 21 September 2026; matched the OnCo record for ITK.
Published in Arthritis Care Res (Hoboken) on 21 September 2026; matched the OnCo record for Tocilizumab.
Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for Floxuridine.
Published in Clin Cancer Res on 21 September 2026; matched the OnCo record for Adavosertib.
Published in Clin Case Rep on 21 September 2026; matched the OnCo record for Renal medullary carcinoma.
Published in Br J Dermatol on 21 September 2026; matched the OnCo record for Mogamulizumab.
Published in J Mater Chem B on 21 September 2026; matched the OnCo record for DLL4.
Published in Adv Sci (Weinh) on 21 September 2026; matched the OnCo record for ATP4B.
Published in Value Health on 21 September 2026; matched the OnCo record for KCNH1.
Published in Head Neck on 21 September 2026; matched the OnCo record for Toripalimab.
Published in Sex Med on 21 September 2026; matched the OnCo record for NR4A3.
Published in Arthritis Rheumatol on 21 September 2026; matched the OnCo record for Emapalumab.
Published in Lab Anim Res on 20 September 2026; matched the OnCo record for Genetically engineered mouse models.
Published in Oncogene on 20 September 2026; matched the OnCo record for Humanised mouse models.
Published in Cancer Causes Control on 20 September 2026; matched the OnCo record for Oncotype DX.
Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Penile cancer.
Published in J Surg Oncol on 20 September 2026; matched the OnCo record for ASXL1.
Published in Crit Rev Oncol Hematol on 20 September 2026; matched the OnCo record for Belzutifan.
Published in Cardiovasc Toxicol on 20 September 2026; matched the OnCo record for HER4.
Published in Br J Haematol on 20 September 2026; matched the OnCo record for Acute lymphoblastic leukaemia.
Published in Acta Biomater on 20 September 2026; matched the OnCo record for CD123.
On September 18, 2026, the Food and Drug Administration approved imlunestrant (Inluriyo) in combination with abemaciclib (Verzenio), for adults with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, with disease progression following at least one line of endocrine therapy.
Published in J Clin Oncol on 18 September 2026; matched the OnCo record for Early-stage classical Hodgkin lymphoma.
Published in Cancer Discov on 18 September 2026; matched the OnCo record for Amivantamab.
Published in Cancer Cell on 18 September 2026; matched the OnCo record for Zoledronic acid.
303 changelog entries, 1 upcoming date, 11 publications, 8 corrections.
Published in Science on 17 September 2026; matched the OnCo record for RaDaR.
Published in Cancer Discov on 17 September 2026; matched the OnCo record for YL201.
Published in Nat Med on 17 September 2026; matched the OnCo record for Diffuse midline glioma, H3 K27-altered.
Published in Ann Oncol on 17 September 2026; matched the OnCo record for Goserelin / leuprolide.
openFDA has a label for "Givinostat".
EMA register: MabCampath (alemtuzumab) Withdrawn, 2001-07-06.
EMA register: Xagrid (anagrelide) Authorised, 2004-11-15.
EMA register: Emend (aprepitant) Authorised, 2003-11-11.
EMA register: Targretin (bexarotene) Authorised, 2001-03-29.
EMA register: Busilvex (busulfan) Withdrawn, 2003-07-09.
EMA register: Xeloda (capecitabine) Authorised, 2001-02-02.
EMA register: Tabrecta (capmatinib) Authorised, 2022-06-20.
EMA register: Carmustine medac (previously Carmustine Obvius) (carmustine) Authorised, 2018-07-18.
EMA register: Korjuny (catumaxomab) Authorised, 2025-02-10.
EMA register: Evoltra (clofarabine) Authorised, 2006-05-29.
EMA register: DepoCyte (cytarabine) Withdrawn, 2001-07-11.
EMA register: Tafinlar (dabrafenib) Authorised, 2013-08-26.
EMA register: Aranesp (darbepoetin alfa) Authorised, 2001-06-08.
EMA register: Vyxeos liposomal (previously Vyxeos) (daunorubicin;cytarabine) Authorised, 2018-08-23.
Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Localised anal squamous cell carcinoma.
Published in Cancer Cell on 16 September 2026; matched the OnCo record for Adebrelimab.
Published in J Clin Oncol on 16 September 2026; matched the OnCo record for Trastuzumab rezetecan.
Published in Nature on 16 September 2026; matched the OnCo record for HLA-C.
Published in Nature on 16 September 2026; matched the OnCo record for PRKCB.
Published in Nature on 15 September 2026; matched the OnCo record for Erythropoietin receptor.
Published in J Clin Oncol on 15 September 2026; matched the OnCo record for STAG2.
Published in Nat Med on 15 September 2026; matched the OnCo record for GFH375.
Published in Cancer Discov on 15 September 2026; matched the OnCo record for MAFB.
Published in Nat Cancer on 14 September 2026; matched the OnCo record for FOLFIRI.
Published in Cell on 14 September 2026; matched the OnCo record for MYH9.
Published in J Clin Oncol on 14 September 2026; matched the OnCo record for Afatinib.
Published in Cell on 14 September 2026; matched the OnCo record for NDRG1.
On September 9, 2026, the Food and Drug Administration granted accelerated approval to sevabertinib (Hyrnuo, Bayer Healthcare Pharmaceuticals Inc.), a kinase inhibitor, for adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations, as detected by an FDA-authorized test.
Accelerated approval (Etcamah).
On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant (Etcamah, AstraZeneca), an estrogen receptor antagonist, in combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer upon detection of estrogen receptor-1 (ESR1) mutation during aromatase inhibitor and CDK4/6 inhibitor therapy, based on an FDA-authorized test.
NDA 220910 approved as Rasonque: adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 26, 2026, the Food and Drug Administration approved daraxonrasib (RASONQUE, Revolution Medicines, Inc.), an inhibitor of the RAS GTPase family, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or who are not candidates for multiagent systemic therapy.
On August 25, 2026, the Food and Drug Administration approved zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals) in combination with fluoropyrimidine- and platinum-containing chemotherapy and tislelizumab-jsgr (Tevimbra, BeOne Medicines USA, Inc.), as first-line treatment for adults with HER2-positive (IHC 3+ or IHC 2+/ISH+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test, and in combination with fluoropyrimidine-, and platinum-containing chemotherapy, as first-line treatment for adults with HER2-positive (IHC 3+) unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma, as detected by an FDA-approved test.: dolutegravir.
On August 13, 2026, the Food and Drug Administration granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.
On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen.
Subcutaneous formulation (PALOMA-3).
On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic androgen pathway modulation-naïve or-sensitive (mAPMN/S) prostate cancer (previously referred to as metastatic hormone-sensitive prostate cancer).
On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).
On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer without a PIK3CA mutation detected following progression on or after treatment with at least one line of endocrine therapy in the metastatic setting.
On July 14, 2026, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients two years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options.
On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvant treatment after cystectomy (surgery to remove the bladder) for adults with muscle invasive bladder cancer (MIBC).
Programme deprioritised after regulatory feedback on Duravelo-2 design.
For All Regions Other Than the European Union (EU) and Others Accepting Cycle 2 Day 1: Observed Serum Concentration (Ctrough) of Amivantamab at Steady State: Arm A: Lazertinib With Amivantamab SC-CF 206 micrograms per milliliters (mcg/ml) versus Arm B: Lazertinib With Amivantamab Intravenous (IV) Infusion 144 micrograms per milliliters (mcg/ml).
Breast Cancer Gene (BRCA) Subgroup: Radiographic Progression-free Survival (rPFS) Assessed by Investigator: BRCA Subgroup: Placebo With Abiraterone Acetate Plus Prednisone 25.99 months, hazard ratio 0.515.
Overall Survival (OS): Nofazinlimab + Lenvatinib 21.6 months versus Placebo + Lenvatinib 18.5 months.
Major Pathological Response (MPR) - IASLC Method: Osimertinib + Chemo 25.6 % versus Osimertinib 24.8 % versus Placebo + Chemo 1.7 %.
Adjusted Time-Averaged Nivolumab Serum Concentration Over the First 28 Days (Cavgd28-Nivo) on Natural Logarithmic Scale: Nivo + Rela FDC SC 4.141 ug/ml versus Nivo + Rela FDC IV 3.901 ug/ml.
Adjusted Geometric Mean Serum Concentration of Nivolumab Over 28 Days (Cavgd28) on Original Scale: Nivolumab SC 77.373 μg/ml versus Nivolumab IV 36.875 μg/ml versus Nivo SC Process C 75.504 μg/ml versus Nivo SC Process D 75.596 μg/ml.
Progression Free Survival (PFS): Treatment Arm A: Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 8.4 months versus Treatment Arm B: Placebo for Osimertinib (AZD9291), Pemetrexed, Cisplatin or Carboplatin 4.4 months, hazard ratio 0.43.
Time to Discontinuation of Study Treatment Due to Adverse Event (TTDAE) (From Interim Analysis): Asciminib 16 participants versus Nilotinib 34 participants, hazard ratio 0.45.
Median disease-free survival 9.30 against 5.55 months (hazard ratio 0.79, p=0.107): primary endpoint not met.
Red Blood Cell-transfusion Independence (RBC-TI) ≥ 12 Weeks (RBC-TI 12): Treatment 23.08 % versus Control 13.33 %.
PFS and OS significantly improved at interim analysis (numbers presented ASCO 2026).
Overall survival 17.7 vs 18.0 months (HR 0.92, p 0.32) overall and 20.4 vs 20.4 months (HR 1.05) in PIK3CA/AKT1/PTEN-altered tumours; PFS 5.6 vs 5.1 months (HR 0.72).
Co-primary endpoints including OS met (July 2026); numbers pending.
Met the primary overall survival endpoint at the pre-specified interim analysis (Amgen, 8 September 2026); progression-free survival and response rate also improved; figures not yet disclosed.
Stopped early; primary endpoint not met.
Marketing authorisation withdrawn in the European Union in 2026: Authorised May 2021; marketing authorisation withdrawn at Secura Bio's request 16 Feb 2026 (commercial reasons).
Marketing authorisation withdrawn in the European Union in 2025: Mimpara: authorised 22 Oct 2004; marketing authorisation withdrawn 18 Dec 2025.
Marketing authorisation withdrawn in the European Union in 2025: MAA withdrawn 22 Jul 2025 after CHMP signalled a negative opinion (response rate, deaths, manufacturing).
A 2025 EU regulation that gives patients electronic access to their health records across the Union and creates national bodies that can grant researchers, regulators and companies permission to use anonymised or pseudonymised health data, phased in over the rest of the decade.
Everything above is read at build time from snapshots and records already in the repository; nothing is fetched when the page is viewed. Where each kind comes from and how often its source refreshes, from the workflow schedules in .github/workflows:
FDA Oncology Center of Excellence approval notifications (public/fda/recent.json), dated approvals recorded on product pages, and European Commission authorisations from the regional approvals table with an EPAR or regulator link.
Refresh: FDA feed Wednesdays 06:07 UTC (refresh-fda.yml); EU rows checked against the EMA register Wednesdays 06:37 UTC (refresh-regional.yml); product pages by hand.
Dated withdrawals recorded on product pages and withdrawn EU authorisations in the regional approvals table, each with a source link.
Refresh: Same schedule as approvals.
Trials in the corpus with a reported year and structured outcomes, linked to the primary paper, sponsor release or registry entry the outcome cites.
Refresh: Curated by hand; ClinicalTrials.gov status refreshed Mondays 06:17 UTC (refresh-trials.yml).
The newest Europe PMC matches for every product, target, cancer and technology (public/papers), journal versions of tracked preprints, and papers the roadmap watch found for landmark trials. One entry per DOI, however many records it matched.
Refresh: Literature snapshot Tuesdays 05:41 UTC (refresh-papers.yml); roadmap watch Thursdays 05:29 UTC (roadmap-watch.yml).
bioRxiv, medRxiv, Research Square and other preprints of the last 90 days that match a target, product or technology query (public/preprints). Not peer reviewed.
Refresh: Wednesdays 06:17 UTC (refresh-preprints.yml).
Statutes, regulations, guidance and court rulings in the law index, dated to the year the instrument was made, each linked to its primary text.
Refresh: Curated by hand; new instruments are added when they are enacted.
Changes the nightly bot proposes for the corpus from the FDA feed, the EMA register and registry status changes (public/proposals/latest.json). Proposals, not facts: each waits for a human to apply it.
Refresh: Daily 03:23 UTC (propose.yml).
OnCo's own weekly issue: what changed, regulatory events, upcoming readouts and what the journals published.
Refresh: Mondays 07:31 UTC (newsletter.yml); the archive is rebuilt with every deploy.
Dates are shown at the precision the source gives: a year-only law or authorisation is grouped under its year, never given a day. Papers are matched to records by their literature queries, so a code or a common word can pull in an unrelated paper; the record chips tell you what matched. Not medical advice.